Obesity is a chronic disease influenced by metabolic pathways, hormonal signals, genetics, and long-standing behavioral patterns
Survey respondents who were aware of GLP - 1 drugs yet were not using them cited reasons such as the high cost (treatments currently cost over $1,000 per month), limited insurance coverage, required weekly injections for sustained results and concerns about side effects such as nausea
These findings suggest that the gut microbiota may promote the onset and progression of EDC through the propagation of inflammatory signals that activate both peripheral and central immune responses
GLP-Squared leverages both GLP-1 and GIP receptor activationa mechanism shown in recent SURMOUNT trials to produce weight loss exceeding either drug alone
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort
In two studies with adults who had obesity and moderate to severe OSA over a 52-week period, participants who received Zepbound experienced a "statistically significant and clinically meaningful reduction" in episodes of shallow breathing or temporary pauses in breathing while asleep compared to those who received a placebo, the FDA said
